Effect of N-acetyl cysteine versus placebo on clinical outcomes in patients with acute radicular lumbar pai

Phase 3

Conditions: Acute radicular lumbar pain.
Spinal enthesopathy, lumbar region
M46.06

Registration Number: IRCT20120215009014N381

Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 60

Inclusion Criteria

Age of 18 to 65 years,
Acute lumbar radicular pain due to disc herniation,
A minimum pain intensity score of 4 or more based on the VAS,
A minimum functional disability score of 30 or more based on disability index questionnaire,
Symptoms start between the last 2 to 12 weeks,
Lack of proper response to NSAIDs and corticosteroids

Exclusion Criteria

Taking herbal medications or products or other supplements in the last 3 months,
Spinal canal stenosis or intervertebral disc degeneration,
Patients with progressive and severe motor symptoms,
History of neuropathy for other reasons,
History of lumbar surgery,
Existence of any malignancy,
Pregnancy or breastfeeding,
Chronic liver or kidney disease,
Hypersensitivity to N-acetyl cysteine

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Functional disability. Timepoint: Before the intervention and in second, fourth, and eighth weeks after the intervention. Method of measurement: Using Oswestry Disability Index (ODI).;The severity of pain. Timepoint: Before the intervention and in second, fourth, and eighth weeks after the intervention. Method of measurement: Using Visual Analog Scale (VAS).;Response to treatment. Timepoint: 8 weeks after the intervention. Method of measurement: Using Global Response Assessment (GRA).

Secondary Outcome Measures

Name	Time	Method
Gastrointestinal or systemic adverse effects. Timepoint: In the second, fourth, and eighth weeks after the intervention. Method of measurement: By taking history.